⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KPTI News
Karyopharm Therapeutics Inc.
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
prnewswire.com
KPTI
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
prnewswire.com
KPTI
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
KPTI
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
prnewswire.com
KPTI
Form 8-K
sec.gov
KPTI
Form 8-K
sec.gov
KPTI
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
prnewswire.com
KPTI
Karyopharm to Participate at Upcoming Investor Conferences
prnewswire.com
KPTI
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
prnewswire.com
KPTI
Form 8-K
sec.gov
KPTI